Chugai investing S$476m more into S'pore facility
Funds will be used to boost Japanese drug maker's local employee base and antibody R&D pipeline
Singapore
JAPANESE drug maker Chugai Pharmaceutical on Wednesday announced that it will invest S$476 million from now until 2021 into its research institute in Singapore, Chugai Pharmabody Research (CPR).
When CPR first set up its corporate laboratory here in 2012 to develop antibody drugs, it planned to pour about S$200 million into antibody research over the subsequent five years.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
Vietnam tycoon appeals against US$27 billion fraud death sentence
US announces new restrictions on firearm exports
Central banks will probably only cut half as much as they hiked
US consumer sentiment falls as inflation expectations climb
HSBC wins £1.3 billion suit over Disney film finance scandal
WTO countries to reboot dispute reform negotiations